Bionure 

Bionure is developing new therapeutics capable of slowing down, stopping and reversing damage to nerve cells.

OWNER

Mar Massó (See Profile)

Sector

Therapeutics

Stage

Development, market readiness, clinical trial

Country

Spain

Preclinical assays show axonal protection and remyelination

Orphan drug designation achieved in EU & US for first target, Acute Optic Neuritis

Candidate drug BN201covered by Composition of Matter patents in major countries until 2031

This information is confidential, do not share or copy.

Under evaluation at least till: 31st of December

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

    ©2019 BioExpert Network

    About cookies

    This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

    If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

    ACEPTAR
    Aviso de cookies

    Log in with your credentials

    or    

    Forgot your details?

    Create Account

    Skip to toolbar